First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II)
Introduction Despite its increasing use, first-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX), hereinafter referred to as first-line bidirectional therapy, has never been prospectively investigated in patie...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-03-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/11/3/e044811.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846164627287703552 |
|---|---|
| author | Joost Nederend Robin J. Lurvink Paulien Rauwerdink Koen P. Rovers Emma C.E. Wassenaar Maarten J. Deenen Clément J.R. Huysentruyt |
| author_facet | Joost Nederend Robin J. Lurvink Paulien Rauwerdink Koen P. Rovers Emma C.E. Wassenaar Maarten J. Deenen Clément J.R. Huysentruyt |
| author_sort | Joost Nederend |
| collection | DOAJ |
| description | Introduction Despite its increasing use, first-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX), hereinafter referred to as first-line bidirectional therapy, has never been prospectively investigated in patients with colorectal peritoneal metastases (CPM). As a first step to address this evidence gap, the present study aims to assess the safety, feasibility, antitumour activity, patient-reported outcomes, costs and systemic pharmacokinetics of first-line bidirectional therapy in patients with isolated unresectable CPM.Methods and analysis In this single-arm, phase II study in two Dutch tertiary referral centres, 20 patients are enrolled. Key eligibility criteria are a good performance status, pathologically proven isolated unresectable CPM, no previous palliative systemic therapy for colorectal cancer, no (neo)adjuvant systemic therapy ≤6 months prior to enrolment and no previous pressurised intraperitoneal aerosol chemotherapy (PIPAC). Patients receive three cycles of bidirectional therapy. Each cycle consists of 6 weeks first-line palliative systemic therapy at the medical oncologists’ decision (CAPOX-bevacizumab, FOLFOX-bevacizumab, FOLFIRI-bevacizumab or FOLFOXIRI-bevacizumab) followed by ePIPAC-OX (92 mg/m2) with an intraoperative bolus of intravenous leucovorin (20 mg/m2) and 5-fluorouracil (400 mg/m2). Study treatment ends after the third ePIPAC-OX. The primary outcome is the number of patients with—and procedures leading to—grade ≥3 adverse events (Common Terminology Criteria for Adverse Events V.5.0) up to 4 weeks after the last procedure. Key secondary outcomes include the number of bidirectional cycles in each patient, treatment-related characteristics, grade ≤2 adverse events, tumour response (histopathological, cytological, radiological, biochemical, macroscopic and ascites), patient-reported outcomes, systemic pharmacokinetics of oxaliplatin, costs, progression-free survival and overall survival.Ethics and dissemination This study is approved by the Dutch competent authority, a medical ethics committee and the institutional review boards of both study centres. Results will be submitted for publication in peer-reviewed medical journals and presented to patients and healthcare professionals.Trial registration number NL8303. |
| format | Article |
| id | doaj-art-8f8b3968e29140ac86d4dc0c04cb99b2 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2021-03-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-8f8b3968e29140ac86d4dc0c04cb99b22024-11-17T22:30:09ZengBMJ Publishing GroupBMJ Open2044-60552021-03-0111310.1136/bmjopen-2020-044811First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II)Joost Nederend0Robin J. Lurvink1Paulien Rauwerdink2Koen P. Rovers3Emma C.E. Wassenaar4Maarten J. Deenen5Clément J.R. Huysentruyt6Department of Radiology, Catharina Hospital, Eindhoven, The NetherlandsDepartment of Surgery, Catharina Hospital, Eindhoven, The NetherlandsDepartment of Surgery, Sint Antonius Ziekenhuis, Nieuwegein, The NetherlandsDepartment of Surgery, Catharina Hospital, Eindhoven, The NetherlandsDepartment of Surgery, Sint Antonius Ziekenhuis, Nieuwegein, The NetherlandsDepartment of Clinical Pharmacy, Catharina Hospital, Eindhoven, The NetherlandsDepartment of Pathology, Catharina Hospital, Eindhoven, The NetherlandsIntroduction Despite its increasing use, first-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX), hereinafter referred to as first-line bidirectional therapy, has never been prospectively investigated in patients with colorectal peritoneal metastases (CPM). As a first step to address this evidence gap, the present study aims to assess the safety, feasibility, antitumour activity, patient-reported outcomes, costs and systemic pharmacokinetics of first-line bidirectional therapy in patients with isolated unresectable CPM.Methods and analysis In this single-arm, phase II study in two Dutch tertiary referral centres, 20 patients are enrolled. Key eligibility criteria are a good performance status, pathologically proven isolated unresectable CPM, no previous palliative systemic therapy for colorectal cancer, no (neo)adjuvant systemic therapy ≤6 months prior to enrolment and no previous pressurised intraperitoneal aerosol chemotherapy (PIPAC). Patients receive three cycles of bidirectional therapy. Each cycle consists of 6 weeks first-line palliative systemic therapy at the medical oncologists’ decision (CAPOX-bevacizumab, FOLFOX-bevacizumab, FOLFIRI-bevacizumab or FOLFOXIRI-bevacizumab) followed by ePIPAC-OX (92 mg/m2) with an intraoperative bolus of intravenous leucovorin (20 mg/m2) and 5-fluorouracil (400 mg/m2). Study treatment ends after the third ePIPAC-OX. The primary outcome is the number of patients with—and procedures leading to—grade ≥3 adverse events (Common Terminology Criteria for Adverse Events V.5.0) up to 4 weeks after the last procedure. Key secondary outcomes include the number of bidirectional cycles in each patient, treatment-related characteristics, grade ≤2 adverse events, tumour response (histopathological, cytological, radiological, biochemical, macroscopic and ascites), patient-reported outcomes, systemic pharmacokinetics of oxaliplatin, costs, progression-free survival and overall survival.Ethics and dissemination This study is approved by the Dutch competent authority, a medical ethics committee and the institutional review boards of both study centres. Results will be submitted for publication in peer-reviewed medical journals and presented to patients and healthcare professionals.Trial registration number NL8303.https://bmjopen.bmj.com/content/11/3/e044811.full |
| spellingShingle | Joost Nederend Robin J. Lurvink Paulien Rauwerdink Koen P. Rovers Emma C.E. Wassenaar Maarten J. Deenen Clément J.R. Huysentruyt First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II) BMJ Open |
| title | First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II) |
| title_full | First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II) |
| title_fullStr | First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II) |
| title_full_unstemmed | First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II) |
| title_short | First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II) |
| title_sort | first line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy oxaliplatin for isolated unresectable colorectal peritoneal metastases protocol of a multicentre single arm phase ii study crc pipac ii |
| url | https://bmjopen.bmj.com/content/11/3/e044811.full |
| work_keys_str_mv | AT joostnederend firstlinepalliativesystemictherapyalternatedwithelectrostaticpressurisedintraperitonealaerosolchemotherapyoxaliplatinforisolatedunresectablecolorectalperitonealmetastasesprotocolofamulticentresinglearmphaseiistudycrcpipacii AT robinjlurvink firstlinepalliativesystemictherapyalternatedwithelectrostaticpressurisedintraperitonealaerosolchemotherapyoxaliplatinforisolatedunresectablecolorectalperitonealmetastasesprotocolofamulticentresinglearmphaseiistudycrcpipacii AT paulienrauwerdink firstlinepalliativesystemictherapyalternatedwithelectrostaticpressurisedintraperitonealaerosolchemotherapyoxaliplatinforisolatedunresectablecolorectalperitonealmetastasesprotocolofamulticentresinglearmphaseiistudycrcpipacii AT koenprovers firstlinepalliativesystemictherapyalternatedwithelectrostaticpressurisedintraperitonealaerosolchemotherapyoxaliplatinforisolatedunresectablecolorectalperitonealmetastasesprotocolofamulticentresinglearmphaseiistudycrcpipacii AT emmacewassenaar firstlinepalliativesystemictherapyalternatedwithelectrostaticpressurisedintraperitonealaerosolchemotherapyoxaliplatinforisolatedunresectablecolorectalperitonealmetastasesprotocolofamulticentresinglearmphaseiistudycrcpipacii AT maartenjdeenen firstlinepalliativesystemictherapyalternatedwithelectrostaticpressurisedintraperitonealaerosolchemotherapyoxaliplatinforisolatedunresectablecolorectalperitonealmetastasesprotocolofamulticentresinglearmphaseiistudycrcpipacii AT clementjrhuysentruyt firstlinepalliativesystemictherapyalternatedwithelectrostaticpressurisedintraperitonealaerosolchemotherapyoxaliplatinforisolatedunresectablecolorectalperitonealmetastasesprotocolofamulticentresinglearmphaseiistudycrcpipacii |